What the changes say
- Rezdiffra commercialization now emphasizes reimbursement, EU pricing, specialty distributors, competition from over 140 MASH drugs, and post-approval regulatory compliance.
- New policy risks include potential U.S. most-favored-nation pricing, FDA disruption from administration changes, and expanded AI and control obligations.
- Financing changed to Blue Owl’s potential $500 million senior secured facilities, while foreign trials and open-label designs receive more attention.
- Several shareholder and data-protection risks were retained but updated for current regulatory, cybersecurity, and financing circumstances.
What changed since the prior 10-K
New
- NewRisks Related to the Commercialization and Continued Approval of Rezdiffra
If we are unable to obtain or maintain adequate coverage and reimbursement from government or third-party payors for Rezdiffra or, if approved, any other product candidates, our prospects for generating revenue may be adversely affected
Insufficient Medicare, Medicaid, managed-care, or private insurance coverage could prevent patients from affording Rezdiffra and limit revenue.
- NewRisks Related to the Commercialization and Continued Approval of Rezdiffra
Federal legislative and regulatory efforts to implement reference pricing or most-favored-nation pricing models could impact our product revenues and harm our business
U.S. most-favored-nation or reference pricing proposals, tariffs, and potential CMS actions could reduce Rezdiffra revenues.
- NewRisks Related to the Commercialization and Continued Approval of Rezdiffra
including information arising from real-world use. Other regulatory elements may also be added by other health authorities throughout the world
FDA, EMA, or other regulatory findings about Rezdiffra, its manufacturing, or compliance could restrict sales, trigger recalls, or remove approval.
- NewRisks Related to the Commercialization and Continued Approval of Rezdiffra
There are over 140 drugs in development for the potential treatment of MASH by companies ranging in size from private biotech companies to large pharmaceutical organizations. See the section titled “Business—Competition” in this Annual Report for more information
More than 140 MASH drugs in development could intensify competition and make Rezdiffra commercialization, differentiation, and talent recruitment harder.
- NewRisks Related to the Commercialization and Continued Approval of Rezdiffra
EU pricing and reimbursement regulations may materially affect our ability to market and receive coverage for Rezdiffra in the EU Member States
Different EU Member State pricing, reimbursement, and profitability controls could delay Rezdiffra launches and reduce coverage or revenue.
- NewRisks Related to Product Development and Regulatory Approval
We may in the future conduct certain clinical trials for our product candidates outside of the U.S. However, the FDA may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business
The FDA may reject foreign clinical-trial data if it does not meet requirements for U.S. populations, investigators, validity, or inspection.
- NewRisks Related to Product Development and Regulatory Approval
review, the FDA’s marketing application review goal is shortened to six months, as opposed to ten months under standard review
FDA or other regulators may deny or withdraw breakthrough-therapy or priority-review designations, leaving development and review timelines unchanged.
- NewRisks Related to Our Dependence on Third Parties
Using specialty distributors to market and sell Rezdiffra in certain jurisdictions outside of the United States subjects us to certain risks
Specialty distributors outside the U.S. may undersell Rezdiffra, breach laws, mishandle inventory or safety information, or fail financially.
- NewRisks Related to Government Regulation
adverse impact on our reputation, business, financial condition, results of operations and prospects and the value of our common stock
FDA and other agency funding, staffing, leadership, or policy disruptions could delay approvals, clinical-trial feedback, and regulatory submissions.
- NewRisks Related to Ownership of Our Common Stock
In addition, due to one or more of the foregoing factors in one or more future quarters, our results of operations may fall below the expectations of securities analysts and investors. In the event any of the foregoing occur, the market price of our common stock could be highly volatile and may materially decline
Charter, bylaw, and Delaware anti-takeover provisions could block favorable acquisitions, management changes, or premiums for common stockholders.
- NewRisks Related to Ownership of Our Common Stock
leakage, loss of consensus reality, inequality, environmental harms, and other harms may flow from our development, use, or deployment of AI technologies
Biased or socially harmful AI models could create reputational, competitive, regulatory, or legal problems as Madrigal develops or uses AI.
- NewRisks Related to Ownership of Our Common Stock
technology, implement additional financial and management controls, reporting systems and procedures and hire additional accounting and finance staff
Weaknesses in new financial systems, controls, or reporting processes could cause inaccurate filings, restatements, investigations, fines, or litigation.
- NewRisks Related to Ownership of Our Common Stock
Taxing authorities could challenge our historical and future tax positions or our allocation of taxable income among our subsidiaries and we may incur additional tax liabilities
- NewRisks Related to Ownership of Our Common Stock
Volatility in foreign currency exchange rates could have a material adverse effect on our operating results
Dropped
- DroppedRisks Related to the Commercialization and Continued Approval of Rezdiffra
We may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business
- DroppedRisks Related to the Commercialization and Continued Approval of Rezdiffra
in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs
- DroppedRisks Related to the Commercialization and Continued Approval of Rezdiffra
the prices of prescription drugs in the government health benefit programs. The IRA or other legislative changes could impact the market conditions for our product candidate
General risk that pricing rules or payor coverage policies could harm Rezdiffra commercialization.
- DroppedRisks Related to the Commercialization and Continued Approval of Rezdiffra
be successful in these trials or in obtaining such regulatory approval, which may materially adversely affect our prospects and the value of our common stock
Reimbursement delays, limited coverage, mandatory discounts, or rebates could reduce drug payments below costs.
- DroppedRisks Related to the Commercialization and Continued Approval of Rezdiffra
Governments outside the United States tend to impose strict price controls, which may adversely affect our revenues, if any
Government and payor efforts to cap healthcare costs or specialty-drug prices could limit coverage and reimbursement.
- DroppedRisks Related to Product Development and Regulatory Approval
data become available. Differences between preliminary or interim data and final data could significantly harm our business prospects
- DroppedRisks Related to our Business Operations, Employee Matters and Managing Growth
We may enter into out-licenses or pursue collaborative relationships with entities in foreign jurisdictions outside of the United States and Europe
- DroppedRisks Related to Ownership of Our Common Stock
A small number of our stockholders beneficially own a substantial amount of our outstanding common stock and may be deemed to have substantial control over us; therefore, your ability to influence corporate matters may be limited
- DroppedRisks Related to Ownership of Our Common Stock
stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management, which may depress the trading price of our common stock
- DroppedRisks Related to Ownership of Our Common Stock
contest involving our company. The existence of these provisions could negatively affect the price of our common stock and limit opportunities for you to realize value in a corporate transaction
Failure of the MAESTRO-NASH OUTCOMES trial or regulatory efforts to expand Rezdiffra’s patient population.
- DroppedRisks Related to Ownership of Our Common Stock
We may use and integrate artificial intelligence into our business processes both in our own development and implementation of models and through the adoption of commercially available tools. Use of this technology presents risks and challenges that could affect our business
Reworded
- 89% rewrittenRisks Related to Government Regulation
European data collection is governed by restrictive regulations governing the use, processing and cross-border transfer of personal information
The GDPR risk now expressly covers both EU GDPR and UK GDPR and adds obligations concerning sensitive-data processing, consent, legal bases, and disclosures.
- 84% rewrittenRisks Related to the Commercialization and Continued Approval of Rezdiffra
If we are unable to compete successfully, it will materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock
The risk now identifies FDA accelerated approval and EC conditional marketing authorization, plus the fully enrolled Phase 3 MAESTRO-NASH OUTCOMES trial to expand Rezdiffra’s population.
- 72% rewrittenRisks Related to Our Financial Position and Need for Capital
Our Financing Agreement contains restrictive and financial covenants that may limit our operating flexibility
The financing risk changed from Hercules’ $250 million loan agreement to Blue Owl facilities of up to $500 million, including a $350 million initial term loan and $150 million delayed draw.
Was: Our Loan and Security Agreement contains restrictive and financial covenants that may limit our operating flexibility
- 67% rewrittenRisks Related to Ownership of Our Common Stock
If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, investors’ views of us and, as a result, the value of our common stock
The control risk now adds potential system upgrades, financial and management controls, reporting procedures, and accounting and finance staff.
- 62% rewrittenRisks Related to the Commercialization and Continued Approval of Rezdiffra
Like all medicinal products, Rezdiffra remains subject to ongoing regulatory review, and if we fail to comply with regulations or satisfy our post-approval commitments, we could lose our approval and the sale of Rezdiffra could be suspended
The regulatory-compliance risk now covers both FDA accelerated approval and EC conditional marketing authorization for Rezdiffra.
Was: Rezdiffra remains subject to ongoing regulatory review, and if we fail to comply with continuing regulations, we could lose our approval and the sale of Rezdiffra could be suspended
- 62% rewrittenRisks Related to Ownership of Our Common Stock
The amendment of any of these provisions, with the exception of the ability of our board of directors to issue shares of preferred stock and designate any rights, preferences and privileges thereto, would require approval by the holders of at least 80% of our then-outstanding common stock
The anti-takeover discussion retains Delaware Section 203 and the 15% ownership threshold, with no substantive change identified.
- 59% rewrittenRisks Related to Ownership of Our Common Stock
A failure of our information technology infrastructure and cybersecurity threats may adversely affect our business and operations
Cybersecurity wording now expressly adds cybersecurity incidents and data breaches to the listed threats.
- 53% rewrittenRisks Related to Product Development and Regulatory Approval
We cannot be certain that any of our ongoing or future clinical trials will be successful, and any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications
The revised text adds open-label trial risks, including patient awareness and bias that may exaggerate Rezdiffra’s apparent therapeutic effect.
- 45% rewrittenRisks Related to the Commercialization and Continued Approval of Rezdiffra
We operate in a highly competitive and changing environment, and if we are unable to adapt to our environment, we may be unable to compete successfully
- 43% rewrittenRisks Related to Product Development and Regulatory Approval
Breakthrough therapy or priority review by the FDA for any product candidate may not lead to faster development, regulatory review or approval processes, and it does not increase the likelihood that our product candidates will receive marketing approval
- 40% rewrittenRisks Related to Ownership of Our Common Stock
Our NOLs have been fully offset by a valuation allowance due to uncertainties surrounding our ability to realize these tax benefits
- 37% rewrittenRisks Related to Product Development and Regulatory Approval
If we fail to successfully develop and commercialize our other product candidates, we may be unable to grow our business
Was: If we fail to develop and commercialize other product candidates, we may be unable to grow our business
- 29% rewrittenRisks Related to Ownership of Our Common Stock
Sales of a significant number of shares of our common stock in the public markets or significant short sales of our common stock, or the perception that such sales could occur, could depress the market price of our common stock and impair our ability to raise capital
- 28% rewrittenRisks Related to our Business Operations, Employee Matters and Managing Growth
We expect to continue to expand our development and commercialization capabilities, and as a result, we may encounter challenges in managing our growth, which could disrupt our operations
- 28% rewrittenRisks Related to Our Intellectual Property
Our rights to develop and commercialize resmetirom are subject in part to the terms and conditions of the Roche Agreement
Was: Our rights to develop and commercialize our product are subject in part to the terms and conditions of a license to resmetirom granted to us by Roche
- 26% rewrittenRisks Related to Ownership of Our Common Stock
Changes in tax law could adversely affect our business and financial condition
- 26% rewrittenRisks Related to Government Regulation
The pharmaceutical industry is highly regulated and changes in or revisions to laws and regulations that make gaining regulatory approval, reimbursement and pricing more difficult or subject to different criteria and standards may adversely impact our business, operations or financial results
- 21% rewrittenRisks Related to Our Financial Position and Need for Capital
We have a history of operating losses, expect to incur operating losses in the future and may never achieve or maintain profitability
- 20% rewrittenRisks Related to Government Regulation
Failure to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity, and could negatively affect our operating results and business
All 76 risk factors
Headings as the filing states them, in filing order.
Risks Related to the Commercialization and Continued Approval of Rezdiffra
- 01The commercial success of Rezdiffra will depend on the degree of market acceptance by physicians, patients, third-party payors and others in the health care community
- 02If the sales and marketing capabilities we have established for the commercialization of Rezdiffra are not effective, Rezdiffra may not be successfully commercialized
- 03If we are unable to obtain or maintain adequate coverage and reimbursement from government or third-party payors for Rezdiffra or, if approved, any other product candidates, our prospects for generating revenue may be adversely affectedNew
- 04Federal legislative and regulatory efforts to implement reference pricing or most-favored-nation pricing models could impact our product revenues and harm our businessNew
- 05Like all medicinal products, Rezdiffra remains subject to ongoing regulatory review, and if we fail to comply with regulations or satisfy our post-approval commitments, we could lose our approval and the sale of Rezdiffra could be suspended62% rewritten
- 06including information arising from real-world use. Other regulatory elements may also be added by other health authorities throughout the worldNew
- 07Rezdiffra could develop unexpected safety or efficacy concerns, which would likely have a material adverse effect on us
- 08We operate in a highly competitive and changing environment, and if we are unable to adapt to our environment, we may be unable to compete successfully45% rewritten
- 09There are over 140 drugs in development for the potential treatment of MASH by companies ranging in size from private biotech companies to large pharmaceutical organizations. See the section titled “Business—Competition” in this Annual Report for more informationNew
- 10If we are unable to compete successfully, it will materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock84% rewritten
- 11If we do not obtain regulatory approval of Rezdiffra in foreign jurisdictions, we will not be able to market Rezdiffra in other jurisdictions, which will limit our commercial revenues
- 12EU pricing and reimbursement regulations may materially affect our ability to market and receive coverage for Rezdiffra in the EU Member StatesNew
- 13If the FDA or other applicable regulatory authorities approve generic products that compete with Rezdiffra, the sales of Rezdiffra would be adversely affected
- 14We currently rely on a limited number of specialty pharmacies for distribution of Rezdiffra in the United States, and the loss of one or more of these specialty pharmacies or their failure to effectively distribute Rezdiffra could materially harm our business
- 15If estimates of the size of the potential market for Rezdiffra is overstated or data we have used to identify physicians is inaccurate, our ability to earn revenue to support our business could be materially adversely affected
- 16Product liability lawsuits brought against us could cause us to incur substantial liabilities and could limit commercialization of Rezdiffra or any future product candidates that we may develop
Risks Related to Product Development and Regulatory Approval
- 17We cannot be certain that any of our ongoing or future clinical trials will be successful, and any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications53% rewritten
- 18If we fail to successfully develop and commercialize our other product candidates, we may be unable to grow our business37% rewritten
- 19If clinical trials or regulatory approval processes are prolonged, delayed or suspended, we may be unable to advance the development of or commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any revenue from potential product sales
- 20Commercialization of any future product candidates may be delayed by the imposition of additional conditions on our clinical trials by the FDA or any other applicable foreign regulatory authority or the requirement of additional supportive trials by the FDA or such foreign regulatory authority
- 21If we inadvertently fail to comply with foreign regulatory requirements governing human clinical trials and marketing approval for drugs, we could be prevented from selling our drug candidates in such foreign markets, which may adversely affect our operating results and financial condition
- 22We may in the future conduct certain clinical trials for our product candidates outside of the U.S. However, the FDA may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our businessNew
- 23We depend on enrollment of patients in our clinical trials. If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected
- 24Breakthrough therapy or priority review by the FDA for any product candidate may not lead to faster development, regulatory review or approval processes, and it does not increase the likelihood that our product candidates will receive marketing approval43% rewritten
- 25review, the FDA’s marketing application review goal is shortened to six months, as opposed to ten months under standard reviewNew
Risks Related to our Business Operations, Employee Matters and Managing Growth
- 26Our failure to successfully in-license, acquire, develop and market additional product candidates could impair our ability to grow our business
- 27Any strategic transactions we enter into may not be clinically or commercially successful, and may require financing or a significant amount of cash, which could adversely affect our business
- 28We are dependent upon retaining and attracting key personnel, the loss of whose services could materially adversely affect our business, financial condition, results of operations, prospects and the value of our common stock
- 29Our employees, contractors, vendors and partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading laws, which could cause significant liability for us and harm our reputation
- 30We expect to continue to expand our development and commercialization capabilities, and as a result, we may encounter challenges in managing our growth, which could disrupt our operations28% rewritten
- 31We enter into various contracts in the normal course of our business in which we indemnify the other party to the contract. In the event we have to perform under these indemnification provisions, such performance could have a material adverse effect on our business, financial condition and results of operations
Risks Related to Our Dependence on Third Parties
- 32If the third parties on which we rely for the conduct of our clinical trials and results do not perform our clinical trial activities in accordance with our agreements, GCP and related regulatory requirements, we may be unable to obtain regulatory approval for our product candidates or commercialize our products
- 33We have relied on, and expect to continue to rely on, third-party manufacturers to produce Rezdiffra and any future product candidates
- 34Our current and anticipated future dependence upon others for the manufacture of Rezdiffra and any product candidate may adversely affect our future profit margins, if any, and our ability to develop our product candidates and commercialize any products that receive regulatory approval on a timely basis
- 35Using specialty distributors to market and sell Rezdiffra in certain jurisdictions outside of the United States subjects us to certain risksNew
Risks Related to Our Financial Position and Need for Capital
- 36We have a limited operating history and currently only have one commercial product, Rezdiffra, which may make it difficult to evaluate the prospects for our future viability
- 37We have a history of operating losses, expect to incur operating losses in the future and may never achieve or maintain profitability21% rewritten
- 38We have a limited history of recognizing revenue from product sales and may not be able to achieve or maintain long-term sustainable profitability
- 39We may need to raise additional capital to fund our operations, but we face uncertainties with respect to our ability to access capital. If we are unable to raise capital if and when needed, we could be forced to delay, reduce or eliminate our drug development activities or commercialization efforts
- 40Our Financing Agreement contains restrictive and financial covenants that may limit our operating flexibility72% rewritten
- 41Our failure to comply with the covenants or other terms of the Financing Agreement, including as a result of events beyond our control, could result in a default under the Financing Agreement that could materially and adversely affect our business
Risks Related to Government Regulation
- 42Government healthcare reform could materially increase our costs, which could materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock
- 43The pharmaceutical industry is highly regulated and changes in or revisions to laws and regulations that make gaining regulatory approval, reimbursement and pricing more difficult or subject to different criteria and standards may adversely impact our business, operations or financial results26% rewritten
- 44adverse impact on our reputation, business, financial condition, results of operations and prospects and the value of our common stockNew
- 45Failure to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity, and could negatively affect our operating results and business20% rewritten
- 46European data collection is governed by restrictive regulations governing the use, processing and cross-border transfer of personal information89% rewritten
- 47Risks associated with operations outside of the United States could adversely affect our business
Risks Related to Our Intellectual Property
- 48Our success depends on our ability to protect our intellectual property and our proprietary technologies
- 49Our rights to develop and commercialize resmetirom are subject in part to the terms and conditions of the Roche Agreement28% rewritten
- 50We may fail to comply with any of our obligations under agreements pursuant to which we license rights or technology, which could result in the loss of rights or technology that may be material to our business
- 51If we do not obtain protection under the Hatch-Waxman Act and similar foreign legislation by extending the term of patents covering our product or product candidates, our business may be materially harmed
- 52Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents
- 53Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts
- 54We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court
- 55We may not be successful in obtaining or maintaining necessary rights to our product and product candidates through acquisitions and in-licenses
- 56Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed
- 57If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
- 58We may not be able to protect our intellectual property rights throughout the world
Risks Related to Ownership of Our Common Stock
- 59The price of our common stock has been, and may continue to be, volatile
- 60In addition, due to one or more of the foregoing factors in one or more future quarters, our results of operations may fall below the expectations of securities analysts and investors. In the event any of the foregoing occur, the market price of our common stock could be highly volatile and may materially declineNew
- 61The amendment of any of these provisions, with the exception of the ability of our board of directors to issue shares of preferred stock and designate any rights, preferences and privileges thereto, would require approval by the holders of at least 80% of our then-outstanding common stock62% rewritten
- 62Future sales and issuances of our common stock or rights to purchase common stock could result in additional dilution of the percentage ownership of our stockholders and could cause our share price to fall
- 63Sales of a significant number of shares of our common stock in the public markets or significant short sales of our common stock, or the perception that such sales could occur, could depress the market price of our common stock and impair our ability to raise capital29% rewritten
- 64We do not anticipate paying cash dividends on our common stock, and accordingly, stockholders must rely on stock appreciation, if any, for any return on their investment
- 65If securities analysts publish negative evaluations of our stock, the price of our stock could decline
- 66We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives
- 67A failure of our information technology infrastructure and cybersecurity threats may adversely affect our business and operations59% rewritten
- 68leakage, loss of consensus reality, inequality, environmental harms, and other harms may flow from our development, use, or deployment of AI technologiesNew
- 69If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, investors’ views of us and, as a result, the value of our common stock67% rewritten
- 70technology, implement additional financial and management controls, reporting systems and procedures and hire additional accounting and finance staffNew
- 71Our NOLs have been fully offset by a valuation allowance due to uncertainties surrounding our ability to realize these tax benefits40% rewritten
- 72Taxing authorities could challenge our historical and future tax positions or our allocation of taxable income among our subsidiaries and we may incur additional tax liabilitiesNew
- 73Changes in tax law could adversely affect our business and financial condition26% rewritten
- 74Volatility in foreign currency exchange rates could have a material adverse effect on our operating resultsNew
- 75Business disruptions could seriously harm our operations, future revenues and financial condition and increase our costs and expenses
- 76We may be subject to securities litigation, which is expensive and could divert management attention
Other Madrigal Pharmaceuticals 10-Ks
- FY2024 10-K risk factors73 risks
Madrigal is a newly commercial-stage biopharmaceutical company focused entirely on the market acceptance and commercialization of Rezdiffra for MASH. The company relies on single-product viability, third-party manufacturers, specialty pharmacies, and external capital to fund operations.
Filed Feb 26, 2025
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.